Author:
Nazarov V. D.,Makshakov G. S.,Mazing A. V.,Surkova E. A.,Krasnov V. S.,Shumilina M. V.,Totolyan N. A.,Evdoshenko E. P.,Lapin S. V.,Emanuel’ V. L.,Skoromets A. A.
Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. A. N. Boiko, O. O. Favorova, O. G. Kulakova, and E. I. Gusev, “Epidemiology and etiology of multiple sclerosis,” in: Multiple Sclerosis, I. A. Gusev, I. A. Zavalishin, and A. N. Boiko (eds.), Moscow (2004).
2. C. Polman, S. Reingold, B. Banwell, et al., “Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria,” Ann. Neurol., 69, No. 2, 292–302 (2011), doi:
https://doi.org/10.1002/ana.22366
.
3. C. Vasconcelos, J. Aurencao, L. Thuler, et al., “Prognostic factors associated with long-term disability and secondary progression in patients with multiple sclerosis,” Mult. Scler. Relat. Disord., 8, 27–34 (2016), doi:
https://doi.org/10.1016/j.msard.20167.03.011
.
4. M. Tintore, A. Rovira, L. Brieva, et al., “Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS,” Mult. Scler., 7, No. 6, 359–363 (2001), doi:
https://doi.org/10.1177/135245850100700603
.
5. G. Edan, L. Kappos, X. Montalban, et al., “Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT,” J. Neurol. Neurosurg. Psychiatry, 85, No. 11, 1183–1189 (2014), doi:
https://doi.org/10.1136/jnnp-2013-306222
.